Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Stroke Alert With Unexpected Outcome: Thrombolytic Therapy And Intracranial Neoplasms
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
064
To report a case of intravenous (IV) tissue plasminogen activator (tPA) administration in a patient with high-grade glioma and no apparent complications.
Observational studies have suggested that IV thrombolysis may be unfavorable in patients with high-grade gliomas. However, current literature on thrombolysis outcomes in patients with primary brain tumors is largely limited to case reports and may be influenced by publication bias.
A case report and literature review.

A 69-year-old male with no significant past medical history presented to our facility for left-sided hemiplegia, hemisensory loss, neglect, dysarthria and right gaze preference (National Institute of Health Stroke Scale 22). He was last seen normal three hours prior to presentation. An emergent noncontrast Computerized Tomography (CT) scan of the head showed hypo-attenuation in the right parietal lobe and  IV thrombolysis was administered.

Subsequently the patient was noted with abnormal motor activity of his left side, left gaze preference and left-beating nystagmus. He was given IV lorazepam and levetiracetam for suspected seizure activity. An emergent Electroencephalogram showed periodic lateralized epileptiform discharges over the right cerebral hemisphere.

Following IV thrombolysis, the patient had CT angiogram which revealed no large vessel occlusion however a marginally enhancing, and centrally nonenhancing mass within the right parietal lobe with vasogenic edema was elucidated. Repeated noncontrast CT head 24 hours after thrombolytic therapy revealed no evidence of intracerebral hemorrhage. Magnetic Resonance Imaging of the brain with gadolinium revealed a 2.5 cm ring-enhancing mass in the right parietal lobe. The patient underwent right sided craniotomy with resection of the mass and pathology revealed Glioblastoma, IDH-wildtype with MGMT promoter methylation.


Our case suggests that thrombolysis inadvertently administered to a stroke mimic may be potentially safe in patients with high-grade gliomas and acceptable medical comorbidities and performance status. This underlines the need for further prospective studies for validation of this observation.

Authors/Disclosures
David Gritsch, MD, PhD
PRESENTER
Dr. Gritsch has nothing to disclose.
Ehab Y. Harahsheh, MBBS Dr. Harahsheh has nothing to disclose.
Kartik Mangipudi, MD (Mayo Clinic Arizona) Dr. Mangipudi has nothing to disclose.
Bart Demaerschalk, MD, MSc, FRCPC, FÂé¶¹´«Ã½Ó³»­ (Mayo Clinic) Dr. Demaerschalk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Demaerschalk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Demaerschalk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The Neurologist . The institution of Dr. Demaerschalk has received research support from NICHD.